newsfilter
← Latest News
Business Wire·

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322